Valeo Financial Advisors LLC decreased its stake in Hill-Rom Holdings, Inc. (NYSE:HRC) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,990 shares of the medical technology company’s stock after selling 1,896 shares during the period. Hill-Rom makes up 0.9% of Valeo Financial Advisors LLC’s investment portfolio, making the stock its 15th largest holding. Valeo Financial Advisors LLC owned 0.13% of Hill-Rom worth $9,762,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in HRC. Prime Capital Investment Advisors LLC purchased a new position in Hill-Rom in the third quarter valued at about $31,000. FNY Investment Advisers LLC acquired a new position in Hill-Rom during the fourth quarter worth $34,000. CENTRAL TRUST Co raised its holdings in Hill-Rom by 251.9% during the third quarter. CENTRAL TRUST Co now owns 475 shares of the medical technology company’s stock worth $50,000 after purchasing an additional 340 shares during the last quarter. Carroll Financial Associates Inc. purchased a new stake in Hill-Rom during the fourth quarter worth $52,000. Finally, Whittier Trust Co. boosted its position in Hill-Rom by 29.8% during the third quarter. Whittier Trust Co. now owns 649 shares of the medical technology company’s stock worth $68,000 after purchasing an additional 149 shares in the last quarter. 83.03% of the stock is currently owned by hedge funds and other institutional investors.

HRC has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $131.00 price target on shares of Hill-Rom in a research report on Friday. Morgan Stanley raised Hill-Rom from an “equal” rating to an “equal weight” rating and lifted their price target for the stock from $113.00 to $138.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $122.60.

Shares of Hill-Rom stock traded down $3.14 during trading on Friday, hitting $109.67. 41,561 shares of the company were exchanged, compared to its average volume of 290,087. The company has a quick ratio of 1.10, a current ratio of 1.31 and a debt-to-equity ratio of 1.13. Hill-Rom Holdings, Inc. has a fifty-two week low of $93.88 and a fifty-two week high of $117.10. The stock has a market capitalization of $7.36 billion, a price-to-earnings ratio of 48.76, a P/E/G ratio of 1.76 and a beta of 0.83. The firm has a 50 day moving average price of $112.77 and a 200 day moving average price of $106.61.

Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 1st. The medical technology company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.65 by $0.04. Hill-Rom had a return on equity of 21.67% and a net margin of 5.24%. The company had revenue of $782.80 million during the quarter, compared to the consensus estimate of $759.14 million. During the same quarter last year, the business posted $1.63 earnings per share. Hill-Rom’s revenue was up 3.1% compared to the same quarter last year. Analysts predict that Hill-Rom Holdings, Inc. will post 5.53 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 16th were paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend was Friday, December 13th. Hill-Rom’s payout ratio is 16.54%.

In other Hill-Rom news, SVP Andreas G. Frank sold 6,000 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $105.83, for a total transaction of $634,980.00. Following the transaction, the senior vice president now owns 40,004 shares of the company’s stock, valued at approximately $4,233,623.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Deborah Rasin sold 4,739 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $103.97, for a total value of $492,713.83. Following the transaction, the senior vice president now directly owns 31,001 shares in the company, valued at approximately $3,223,173.97. The disclosure for this sale can be found here. Insiders own 0.65% of the company’s stock.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Article: Percentage Decliners

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.